Using dupilumab to help patients with hypereosinophilic syndrome who still have symptoms

A Pilot Phase 2 Study of the Safety and Efficacy of Dupilumab as Add-on Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

This study is testing if adding dupilumab to the treatment of adults with hypereosinophilic syndrome can help reduce their ongoing symptoms.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Ages: 18 Years to 99 Years
• Sex: All
• Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
• Drugs / interventions: mepolizumab, reslizumab, benralizumab, dupilumab
• Locations: 1 site (Bethesda, Maryland)
• Trial ID: NCT06477653 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of dupilumab as an add-on therapy for patients with hypereosinophilic syndrome (HES) who continue to experience symptoms despite treatment with eosinophil-depleting biologics. Participants aged 18 and older will be monitored over 48 weeks, undergoing clinical evaluations, blood tests, and surveys to assess their symptoms and overall health. The study aims to determine if dupilumab can further reduce pulmonary, skin, gastrointestinal, or sinus symptoms in these patients. Participants will have regular visits to track their progress and may undergo additional tests, including a bone marrow biopsy if necessary.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with a documented diagnosis of hypereosinophilic syndrome who are currently receiving eosinophil-lowering biologics but still have moderate symptoms.

Not a fit: Patients who do not have hypereosinophilic syndrome or those whose symptoms are adequately controlled by current treatments may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for patients with persistent symptoms of hypereosinophilic syndrome.

How similar studies have performed: While the use of dupilumab in this specific context is novel, similar studies have shown promising results with dupilumab in other eosinophil-related conditions.

Eligibility criteria

* INCLUSION CRITERIA:

To be eligible to participate in this study, an individual must meet all the following criteria:

1. Age \>=18 years
2. Documented diagnosis of HES with historic AEC\>1.5x10\^9/L on two occasions, no secondary etiology for the eosinophilia despite careful clinical evaluation, and evidence of end organ damage (histologic evidence of tissue infiltration by eosinophils and/or objective evidence of clinical pathology in any organ system that is temporally associated with eosinophilia and not clearly attributable to another cause)
3. Currently receiving treatment with an eosinophil-lowering biologic (mepolizumab, reslizumab, or benralizumab) for a minimum of 24 weeks
4. AEC\<0.5x10\^9/L
5. Residual symptoms after a minimum of 24 weeks of eosinophil-lowering biologic therapy with at least 1 most bothersome symptom of moderate severity (HES-SI score \>=2) consistent with \>=1 of the following diagnoses:

   a. asthma, defined as physician-documented asthma requiring medium to high dose inhaled corticosteroids + long-acting beta agonist b. atopic dermatitis, defined as physician-documented chronic or recurrent inflammatory skin disease

   c. CRSwNP, defined as evidence of rhinosinusitis and nasal polyposis on physical examination or imaging

   d. EoE, defined as biopsy-proven esophageal eosinophilia \>15 eosinophils/high power field
6. For participants who can become pregnant: sexual abstinence or use of highly effective contraception (i.e., partner vasectomy, bilateral tubal ligation, IUD, progestin implants, and other hormonal methods) starting 4 weeks prior to study drug initiation and agreement to use such a method during study participation and for an additional 12 weeks after the end of study drug administration
7. Participation in NIH protocol 94-I-0079 (Activation and function of eosinophils in conditions with blood or tissue eosinophilia)
8. Ability of subject to understand and the willingness to sign a written informed consent document

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Pregnancy or lactation
2. Known allergic reaction to dupilumab or any of the excipients in Dupixent(TM)
3. Febrile illness within 7 days of enrollment
4. Treatment with an investigational drug or other intervention other than mepolizumab, reslizumab, or benralizumab within 12 weeks or 4 half-lives of the investigational agent (whichever is longer).
5. Known or suspected acquired or inborn immunodeficiency disorder, including HIV infection
6. Known diagnosis of eosinophilic granulomatosis with polyangiitis
7. Change in eosinophil-active therapy within the past 6 weeks, including but not limited to topical corticosteroids, leukotriene inhibitors, initiation or change of a food-elimination diet regimen or re-introduction of a previously eliminated food (in patients with gastrointestinal involvement), and proton pump inhibitors (in patients with gastrointestinal involvement)
8. Planned or anticipated major surgical procedure during the study
9. Active parasitic infection
10. History of malignancy within 5 years, excluding completely treated in situ carcinoma of the cervix, or squamous or basal cell carcinoma of the skin
11. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study

For patients with eosinophilic gastrointestinal disease only:

1. Active infection with Helicobacter pylori
2. History of achalasia, Crohn s disease, ulcerative colitis, celiac disease, or prior esophageal surgery
3. Any esophageal stricture unable to be passed with a standard, diagnostic, 9 to 10 mm upper endoscope

Where this trial is running

Bethesda, Maryland

• National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)

Study contacts

• Principal investigator: Amy D Klion, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
• Study coordinator: Amy D Klion, M.D.

Conditions Hypereosinophilic Syndrome; Eosinophil; Monoclonal Antibody; Clinical Trial; Treatment